Onconova Therapeutics Inc Stock Nasdaq
Stocks
US68232V1089
Biotechnology & Medical Research
| Market Cap | 19.39M 16.75M 15.43M 14.45M 27.08M 1.84B 27.5M 182M 71.06M 897M 72.78M 71.23M 3.11B | P/E Ratio 2026 * |
-0.58x | P/E Ratio 2027 * | -0.56x |
|---|---|---|---|---|---|
| Enterprise Value | 19.39M 16.75M 15.43M 14.45M 27.08M 1.84B 27.5M 182M 71.06M 897M 72.78M 71.23M 3.11B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 1.48x |
| Free-Float |
90.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Onconova Therapeutics Inc
| 1 day | -5.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Dukes
CEO | Chief Executive Officer | 67 | 2025-03-30 |
Charles Parker
DFI | Director of Finance/CFO | 46 | 2025-07-04 |
Robert Redfield
CTO | Chief Tech/Sci/R&D Officer | 74 | 2024-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Jack Stover
CHM | Chairman | 73 | 2025-04-14 |
Mary Shoemaker
BRD | Director/Board Member | 64 | 2020-03-31 |
Trafford Clarke
BRD | Director/Board Member | 67 | 2022-12-18 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.13% | +0.55% | - | - | 19.39M | |
| -0.35% | +0.97% | -15.96% | -12.73% | 43.03B | |
| +3.11% | +3.11% | +274.29% | +507.94% | 32.71B | |
| +0.22% | -1.08% | +14.03% | -14.37% | 30.29B | |
| +1.62% | -2.08% | -4.36% | +24.05% | 29.4B | |
| +4.09% | +0.93% | +10.83% | +18.78% | 25.08B | |
| -1.63% | +2.88% | +53.73% | +114.36% | 13.35B | |
| +1.14% | +3.62% | - | - | 13.54B | |
| -0.40% | -1.29% | +6.06% | +7.59% | 12.97B | |
| -0.74% | -1.62% | +105.71% | +76.01% | 12.11B | |
| Average | +0.19% | +1.45% | +55.54% | +90.21% | 23.61B | |
| Weighted average by Cap. | +1.05% | +1.48% | +54.94% | +97.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 13.1M 11.31M 10.43M 9.76M 18.29M 1.25B 18.57M 123M 48M 606M 49.16M 48.12M 2.1B |
| Net income | -36.8M -31.78M -29.29M -27.42M -51.38M -3.5B -52.18M -346M -135M -1.7B -138M -135M -5.9B | -43.7M -37.74M -34.78M -32.56M -61.01M -4.15B -61.96M -411M -160M -2.02B -164M -161M -7B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
